Anúncio
Anúncio
CGEM
Cullinan Therapeutics, Inc. Common Stock
10.91
USDPatrocinado
-0.23
-2.09%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
11.19
+0.28
+2.55%
Relatórios de Lucros CGEM
Rácio de surpresa positiva
CGEM separação 13 de 20 últimas estimativas.
65%
Próximo Relatório
Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.80
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/+3.90%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/+9.59%
Cullinan Therapeutics, Inc. Common Stock earnings per share and revenue
On 06 de nov. de 2025, CGEM reported earnings of -0.77 USD per share (EPS) for Q3 25, beating the estimate of -0.97 USD, resulting in a 21.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analistas forecast an EPS of -0.80 USD, with revenue projected to reach -- USD, implying an aumentar of 3.90% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Cullinan Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cullinan Therapeutics, Inc. Common Stock reported EPS of -$0.77, beating estimates by 21.14%, and revenue of $0.00, 0% as expectations.
How did the market react to Cullinan Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 0.55%, changed from $7.31 before the earnings release to $7.35 the day after.
When is Cullinan Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Cullinan Therapeutics, Inc. Common Stock's next earnings report?
Based on 13
analistas, Cullinan Therapeutics, Inc. Common Stock is expected to report EPS of -$0.80 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio